Divalproex and Uptravi

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Selexipag may increase the blood levels of divalproex sodium. You may need more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects such as headache, jaw pain, reddening of the face, or aching joints. It is important to tell your doctor about all other medications your use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with strong inhibitors of the uridine diphosphate glucuronosyltransferase (UGT) 1A3 and 2B7 enzymes may increase plasma concentrations of selexipag, which are involved in the glucuronidation of its active metabolite. However, data evaluating the interaction are not available.

MANAGEMENT: Caution and clinical monitoring are recommended if selexipag is used with strong UGT 1A3 and UGT 2B7 inhibitors, such as valproic acid.

Divalproex

Generic Name: divalproex sodium

Brand name: Depakote ER, Depakote Sprinkles, Depakote, Depakene, Depacon

Synonyms: Divalproex sodium

What is Divalproex?

Uptravi

Generic Name: selexipag

Brand name: Uptravi, Uptravi Titration Pack

Synonyms: n.a.

What is Uptravi?